Highest-materiality recent filing
Lyell Q1 net loss narrows to $24.2M; ronde-cel PiNACLE on track for pivotal data mid-2027
Net loss $24.2M vs $52.2M a year ago; non-GAAP net loss $37.8M vs $46.3M.
Lyell Q4/FY25 net loss $274.4M; Phase 3 PiNACLE-H2H begins; cash $247.2M
FY25 net loss $274.4M vs $343.0M in FY24; Q4 net loss $140.7M (incl. $66.3M IPR&D for LYL273).
Lyell Immunopharma reports 93% ORR in 3L+ LBCL for ronde-cel at ASH
In 3L+ setting (n=29 evaluable): 93% ORR, 76% CR; median PFS 18 months at 12-month median follow-up.
Lyell reports Q3 net loss $38.8M, cash $320M; acquires LYL273 CAR T for mCRC with 67% ORR
Net loss $38.8M vs $44.6M YoY; non-GAAP net loss $29.1M.
Upfront $40M cash + 1.9M Lyell shares; up to $820M in milestones plus tiered royalties up to 10% on US net sales.
Board appointed CEO Lynn Seely as interim principal financial officer on Oct 31, 2025; also remains CEO and director.
Lyell Immunopharma CFO Charles Newton resigns effective Oct 31, 2025
Charles Newton resigns as CFO and principal financial/accounting officer, effective October 31, 2025.
Net loss of $42.7M in Q2 2025 vs $45.8M YoY; non-GAAP net loss $37.8M.
Lyell Immunopharma raises up to $100M in private placement; initial $50M at $13.32/share
Initial closing of ~$50M from 3,753,752 shares at $13.32/share on July 25, 2025.
Lyell reports LYL314 Phase 1/2 data: 88% ORR, 72% CR in 3L+ LBCL
In efficacy-evaluable 3L+ patients (N=25), ORR 88% (22/25) with 72% CR; median follow-up 9 months.
Lyell Immunopharma reports Q1 net loss $52.2M; LYL314 RMAT designation and pivotal trial on track
Net loss of $52.2M (GAAP) vs $60.7M YoY; non-GAAP net loss $46.3M vs $37.5M YoY.
Lyell Immunopharma to close West Hills facility, cut 73 jobs; CBO resigns
Board approved closure of West Hills manufacturing facility acquired from ImmPACT Bio in 2024.
Lyell Q4 net loss $191.9M; cash $383.5M; IMPT-314 pivotal trials set for mid-2025, early 2026
Net loss of $191.9M in Q4 2024 included $87.2M acquired IPR&D from ImmPACT Bio and $51.3M long-lived asset impairment.
Lyell Immunopharma receives Nasdaq delisting notice for bid price below $1.00
Notice received Jan 23, 2025: common stock bid price below $1.00 for 33 consecutive business days.
Lyell closes ImmPACT Bio acquisition; acquired firm had $136.8M deficit, going concern flag
ImmPACT Bio's audited FY2023 net loss $58.9M, R&D spend $44.0M, accumulated deficit $136.8M.
Lyell reports 94% ORR, 71% CR for IMPT-314 in Phase 1-2 large B-cell lymphoma trial
Objective response rate 94% (16/17) and complete response rate 71% (12/17) in CAR T-naive patients with ≥2 prior therapies.
Lyell Immunopharma completes $30M+stock acquisition of ImmPACT Bio, gains CD19/20 CAR T candidate
Upfront: $30M cash (adjusted for ~$12M ImmPACT cash) plus 37.5M Lyell shares; contingent milestone shares up to 12.5M and low-single-digit royalty.
Lyell to acquire ImmPACT Bio for $30M cash + 37.5M shares; discontinues LYL797, LYL845
Upfront consideration: $30M cash (adjusted for ImmPACT's ~$16M cash) and 37.5M Lyell shares.
Lyell Immunopharma Q2 net loss narrows to $45.8M; LYL797 shows 40% ORR in TNBC
Net loss of $45.8M ($63.9M in Q2 2023); non-GAAP net loss $39.1M ($45.6M).
Lyell reports 40% ORR in TNBC from Phase 1 LYL797; expands into ovarian cancer
ORR of 40% and CBR of 60% at 150e6 CAR T dose in relapsed/refractory TNBC (n=5).
Lyell reports Q1 net loss $60.7M; cash $526.3M; LYL797 data due this quarter
Net loss $60.7M vs $67.0M YoY; non-GAAP net loss $37.5M vs $44.8M.
Lyell reports Q4 net loss $52.9M, full-year loss $234.6M; cash $562.7M supports pipeline into 2027
Net loss $52.9M in Q4 2023 and $234.6M full year; non-GAAP net loss $43.9M Q4 and $177.4M FY.
Lyell Immunopharma reprices ~23.4M underwater stock options to $1.87
Effective Nov 16, 2023, new exercise price set at $1.87 for eligible employee options with original prices $2.61–$17.95.
Lyell Immunopharma Q3 net loss $50.9M; workforce cut 25%; cash runway to 2027
Net loss $50.9M vs $70.3M YoY; non-GAAP net loss $43.0M (flat YoY).
Lyell Immunopharma Q2 net loss $63.9M, no revenue, cash $632.7M; Phase 1 data on track
Net loss of $63.9M for Q2 2023, compared to $36.3M in Q2 2022; non-GAAP net loss $45.6M vs $10.3M.
Lyell Immunopharma Q1 net loss $67M; cash $668M; two Phase 1 trials ongoing
GAAP net loss of $67.0M for Q1 2023, compared to $68.1M in Q1 2022; non-GAAP net loss $44.8M vs $50.0M.
Lyell Immunopharma appoints Lynn Seely as President and CEO, succeeding Elizabeth Homans
Elizabeth Homans steps down as CEO effective Dec 15, 2022; will remain as consultant through June 2024.
Lyell Immunopharma Q3 net loss $70.3M; GSK ends collaboration; LYL797 data delayed to H1 2024
Net loss $70.3M vs $48.9M YoY; non-GAAP net loss $43.7M vs $35.7M.
GSK terminates collaboration with Lyell; NY-ESO-1 programs discontinued
GSK provided termination notice Oct 24, 2022, effective Dec 24, 2022; ends development of LYL132 and LYL331 incorporating Lyell's technologies.
Lyell Immunopharma receives FDA IND clearance for LYL845 TIL therapy for solid tumors
FDA cleared IND for LYL845, an autologous TIL therapy enhanced with Epi-R reprogramming technology.
Lyell Q1 net loss widens to $68.1M; cash $838M; LYL797 trial starts
GAAP net loss $68.1M vs $55.0M YoY; non-GAAP net loss $50.0M vs $32.3M.
Lyell Immunopharma reports Q4/FY2021 net loss $250.2M; cash $898M; two INDs cleared
Net loss $250.2M in FY2021 vs $204.5M in 2020; non-GAAP net loss $147.9M.
Lyell gets FDA IND clearance for LYL797 CAR-T; cGMP facility qualified; amends GSK deal
FDA cleared IND for LYL797, a ROR1-targeted CAR-T incorporating Gen-R and Epi-R; Phase 1 trial to screen TNBC patients by Q1 2022, initial data in 2023.
on June 9, 2025, the Board of Directors (the “Board”) of Lyell Immunopharma, Inc. (the “Company”) increased the authorized size of the Board from seven directors to eight directors and, upon recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Mark Bachleda, Pharm.D., M.B.A., to the Board as a Class I director.
On March 27, 2025, Matthew Lang, J.D. notified the Company of his resignation as Chief Business Officer and from all other offices of the Company, effective April 13, 2025.
On November 22, 2024, Hans Bishop resigned as a member of the Board of Directors (the “Board”) and the Nominating and Corporate Governance Committee of the Board of Lyell Immunopharma, Inc. (the “Company”).
Sumant Ramachandra, M.D., Ph.D., who was the Chief Executive Officer and a director of ImmPACT prior to the consummation of the Merger, was appointed as a Class III director to the Board of Directors of the Company.
On December 15, 2022, Lyell Immunopharma, Inc. (the “Company”) announced that Ms. Elizabeth Homans would step down from her position as Chief Executive Officer and as a member of the Board of Directors (the “Board”) of the Company effective December 15, 2022
On December 14, 2022, Dr. Seely entered into an offer of employment with the Company (the “Seely Offer Letter”), pursuant to which she commenced her role as the Company’s President and Chief Executive Officer on December 15, 2022
On October 23, 2021, the compensation committee (the “Compensation Committee) of the board of directors (the “Board”) of Lyell Immunopharma, Inc. (the “Company”) approved the promotion of Stephen Hill, the Company’s Chief Technical Operations Officer, to the position of Chief Operating Officer, to serve in such position until his successor is appointed or until his earlier resignation or removal. Such promotion will be effective on November 1, 2021.
On September 29, 2021, Dr. Klausner informed the Company that he will be resigning from his position as Executive Chairman of the Company and will no longer be an employee, effective October 1, 2021.
On September 29, 2021, Dr. Richard Klausner, the Chair of the Board of Directors (the “Board”) of Lyell Immunopharma, Inc. (the “Company”) informed the Company that (a) he will take a temporary medical leave of absence and is expected to return in early 2022 (the “Leave”) and (b) he will also be resigning from his position as Executive Chairman of the Company and will no longer be an employee, effective October 1, 2022.
The Board has elected Cathy Friedman, its lead independent director, to serve as the interim Chair of the Board during Dr. Klausner’s absence.
Max materiality 1.00 · Median 0.65 · Most common event earnings